Jacobs Levy Equity Management, Inc Lipocine Inc. Transaction History

Jacobs Levy Equity Management, Inc

  • $24.7 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 14, 2019
SELL
$1.07 - $1.63 $64,244 - $97,868
-60,042 Closed
0 $0
Q3 2018

Nov 14, 2018
SELL
$1.31 - $1.63 $6,377 - $7,934
-4,868 Reduced 7.5%
60,042 $83,000
Q2 2018

Aug 14, 2018
BUY
$1.06 - $1.78 $68,804 - $115,539
64,910 New
64,910 $84,000

About Lipocine Inc.

LPCN Quotes by TradingView
  • Ticker LPCN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,510,800
  • Market Cap $468M
  • Description
  • Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...
More about LPCN
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email